secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001485003-22-000164
Event type: m_and_a
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma updates CT-0508 interim data; merger with Sesen expected to close in 1-2 months
--------------------------------------------------------------------------------

- Updated interim data from CT-0508 Study 101 supports safety profile and tumor infiltration.
- Carisma outlines six pre-clinical and clinical milestones expected in 2023.
- Merger with Sesen expected to close in 1-2 months, subject to stockholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500322000164/0001485003-22-000164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500322000164/sesn-20221212.htm
  HTML page:      https://secwatch.observer/filing/0001485003-22-000164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer